CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis

By afschroeder • January 21, 2026

Park D, Varda M, Yeremian S, Hwang A, Huang C. CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. Target Oncol. 2026 Jan 21. doi: 10.1007/s11523-025-01195-9. Epub ahead of print. PMID: 41559355.

Tags: Fellow, Harbor UCLA, Hematology/Oncology, Publications

Preoperative Thrombocytopenia and Risk of Periprosthetic Joint Infection After Total Knee Arthroplasty: A Propensity-Matched Cohort Study

Wiener JM, Hamad CD, Chun RF, Mehany JD, Yeaman MR, Sheppard WL, Bernthal NM. Preoperative Thrombocytopenia and Risk of Periprosthetic Joint Infection After Total Knee[...]

Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024

Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles[...]

Building families-Implementing balanced sexual and reproductive health: A Joint IFFS and ISA Scientific Statement

Liu PY, Mocanu E, Giudice L, Horton M, Nigdelis MP, Perheentupa A, Sansone A, Corona G, Gianaroli L, Goulis DG. Building families-Implementing balanced sexual and[...]